BR112021024099A2 - Composição farmacêutica para diabetes mellitus - Google Patents
Composição farmacêutica para diabetes mellitusInfo
- Publication number
- BR112021024099A2 BR112021024099A2 BR112021024099A BR112021024099A BR112021024099A2 BR 112021024099 A2 BR112021024099 A2 BR 112021024099A2 BR 112021024099 A BR112021024099 A BR 112021024099A BR 112021024099 A BR112021024099 A BR 112021024099A BR 112021024099 A2 BR112021024099 A2 BR 112021024099A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- diabetes mellitus
- relates
- composition
- vildagliptin
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 abstract 1
- 229960001254 vildagliptin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
composição farmacêutica para diabetes mellitus se refere a invenção de uma composição farmacêutica de inibidores da dipeptidil peptidase-iv (dpp-iv) para uso no tratamento de diabetes mellitus (dm). mais particularmente, a presente invenção se refere a uma forma de dosagem de liberação modificada ou prolongada que compreende uma composição de vildagliptina ou um sal farmaceuticamente aceitável desta com parâmetros físicos e químicos desejados para aperfeiçoamento da adesão do paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921021312 | 2019-05-29 | ||
PCT/IN2020/050480 WO2020240594A1 (en) | 2019-05-29 | 2020-05-29 | A pharmaceutical composition for diabetes mellitus |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021024099A2 true BR112021024099A2 (pt) | 2022-01-11 |
Family
ID=71738258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021024099A BR112021024099A2 (pt) | 2019-05-29 | 2020-05-29 | Composição farmacêutica para diabetes mellitus |
Country Status (7)
Country | Link |
---|---|
BR (1) | BR112021024099A2 (pt) |
CL (1) | CL2021003152A1 (pt) |
CO (1) | CO2021018031A2 (pt) |
CR (1) | CR20220001A (pt) |
MX (1) | MX2021014541A (pt) |
PE (1) | PE20220644A1 (pt) |
WO (1) | WO2020240594A1 (pt) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
WO2016016772A1 (en) * | 2014-07-26 | 2016-02-04 | Wockhardt Limited | A novel modified release pharmaceutical composition of dpp-iv inhibitors or pharmaceutically acceptable salt thereof |
-
2020
- 2020-05-29 CR CR20220001A patent/CR20220001A/es unknown
- 2020-05-29 MX MX2021014541A patent/MX2021014541A/es unknown
- 2020-05-29 WO PCT/IN2020/050480 patent/WO2020240594A1/en active Application Filing
- 2020-05-29 BR BR112021024099A patent/BR112021024099A2/pt unknown
- 2020-05-29 PE PE2021001978A patent/PE20220644A1/es unknown
-
2021
- 2021-11-26 CL CL2021003152A patent/CL2021003152A1/es unknown
- 2021-12-29 CO CONC2021/0018031A patent/CO2021018031A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20220644A1 (es) | 2022-04-28 |
WO2020240594A1 (en) | 2020-12-03 |
CL2021003152A1 (es) | 2022-09-23 |
CO2021018031A2 (es) | 2022-04-19 |
MX2021014541A (es) | 2022-02-11 |
CR20220001A (es) | 2022-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
CY1119582T1 (el) | Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη | |
MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
BRPI0906181A2 (pt) | "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer" | |
CO6361917A2 (es) | Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico | |
BRPI0911273B8 (pt) | composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação | |
PH12020551939A1 (en) | Pharmaceutical composition comprising sglt-2 inhibitor and dpp-iv inhibitor | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
BR112022020643A2 (pt) | Método de tratamento de esteato-hepatite não alcoólica | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
BR112022022024A2 (pt) | Uso de um componente (i) em combinação com um componente (ii), composição farmacêutica, medicamento composto e kit | |
AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
MX2022001647A (es) | Terapia de combinacion con vildagliptina y metformina. | |
UY31790A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona | |
RU2012129839A (ru) | Комбинация теобромина с деконгестантом и ее применение для лечения кашля | |
BR112015012497A2 (pt) | combinações farmacêuticas |